MedPath

Rifadin IV NOVAPLUS

RIFADIN (rifampin capsules USP) and RIFADIN IV (rifampin for injection USP)

Approved
Approval ID

87839f65-cb33-412e-929e-564136501a84

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 21, 2023

Manufacturers
FDA

Sanofi-Aventis U.S. LLC

DUNS: 824676584

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

rifampin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0068-0599
Application NumberNDA050627
Product Classification
M
Marketing Category
C73594
G
Generic Name
rifampin
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateDecember 21, 2023
FDA Product Classification

INGREDIENTS (3)

RIFAMPINActive
Quantity: 600 mg in 10 mL
Code: VJT6J7R4TR
Classification: ACTIB
SODIUM FORMALDEHYDE SULFOXYLATEInactive
Quantity: 10 mg in 10 mL
Code: X4ZGP7K714
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Rifadin IV NOVAPLUS - FDA Drug Approval Details